Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from IQVIA Holdings ( (IQV) ).
On December 9, 2025, IQVIA Holdings Inc. amended its Fifth Amended and Restated Credit Agreement to refinance its term loans and revolving credit commitments into new classes, reduce interest rates on certain loans, and release specific subsidiaries from borrowing obligations. This strategic financial restructuring is likely to enhance IQVIA’s operational efficiency and financial flexibility, potentially strengthening its position in the healthcare analytics and research market.
The most recent analyst rating on (IQV) stock is a Buy with a $248.00 price target. To see the full list of analyst forecasts on IQVIA Holdings stock, see the IQV Stock Forecast page.
Spark’s Take on IQV Stock
According to Spark, TipRanks’ AI Analyst, IQV is a Outperform.
IQVIA Holdings demonstrates strong financial performance and positive technical indicators, supported by strategic corporate moves like the appointment of a Nobel Laureate to the Board. The earnings call highlighted robust growth and future potential, although valuation concerns and challenges in the R&D segment pose risks. Overall, the stock is positioned well for growth, but investors should be mindful of valuation and operational challenges.
To see Spark’s full report on IQV stock, click here.
More about IQVIA Holdings
IQVIA Holdings Inc. operates in the healthcare industry, providing advanced analytics, technology solutions, and contract research services to the life sciences sector.
Average Trading Volume: 1,517,386
Technical Sentiment Signal: Buy
Current Market Cap: $38.46B
See more data about IQV stock on TipRanks’ Stock Analysis page.